Nefiracetam

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameNefiracetam
Drug Alias Name奈非西坦nefiracetamMotivaDMPPATranslon +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor agonistsVoltage-gated calcium channel agonistsGlutamate [NMDA] receptor antagonists +[4] 
TargetsVoltage-gated calcium channelGlutamate [NMDA] receptorGamma-aminobutyric acid A receptor +[4] 
Therapy Area/IndicationsDepressionEpilepsyAlzheimer Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeuren Pharmaceuticals LtdNational Institute Of Neurological Disorders And StrokeDaiichi Sankyo Co Ltd
Active IndicationsN/A
Inactive IndicationsDepressionEpilepsyAlzheimer Disease +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia